DRUG-RESISTANT TUBERCULOSIS

Shruti Rajeev Gautam* and Dr. Dhriti Rajeev Gautam

ABSTRACT

Tuberculosis (TB) may be a global infectious threat that's intense by associate degree increasing incidence of extremely drug-resistant disease. A complete of 1.5 million folks died from TB in 2018 occurred worldwide; 3.3% of those cases resulted from multidrug-resistant infectious disease (MDR-TB) and extensively drug-resistant infectious disease (XDR-TB) strains. Prevalence of multidrug-resistant TB (MDR TB) cases is on the rise in India, and proportions of new cases of MDR. Treatment of drug-susceptible TB conducted under strong national TB programs (NTPs) using standard four-drug therapy and directly observed therapy (DOT) has led to relapse-free cure rates over 95% and dramatic national declines in TB incidence. The current proposal of DOTS and by the World Health Organization highlights the great management strategy to manage MDR-TB. MDR-TB may be an unreal downside and its emergence may be prevented by prompt designation and effective treatment of all TB cases along with the recent emergence of covid-19 that may reverse the latest progress in reducing the worldwide load of TB.

Keywords: TB, HIV/TB, COVID-19 pandemic, Drug-resistant TB, management of DRTB.